Prospective evaluation of proteinuria and renal function in non-diabetic patients with progressive renal disease - PLANET II

Study identifier:D3569C00011

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Randomised, double-blind, 52-wk, parallel-grp multicentre, PIIb study to evaluate effects of rosuvastatin 10mg, rosuvastatin 40mg and atorvastatin 80mg on urinary protein excretion in hypercholesterolaemic non-diabetic patients with moderate proteinuria

Medical condition

hyperlipidemia

Phase

Phase 2

Healthy volunteers

No

Study drug

Rosuvastatin, Atorvastatin

Sex

All

Actual Enrollment

237

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 01 Feb 2006
Primary Completion Date: 01 Jun 2009
Study Completion Date: 01 Jun 2009

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Feb 2015 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria